Glioblastoma, Glioma
Conditions
Brief summary
In this study, the investigators propose to combine retifanlimab with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). The investigators hypothesize that this combination provides a powerful synergy between RT and immune modulators to produce more robust anti-tumor immune response, induce tumor regression and improve overall survival.
Interventions
DRUGEpacadostat
-All BID doses will be taken in the morning and evening, approximately 12 hours apart
DRUGBevacizumab
-The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes
RADIATIONRadiation therapy
-The gross tumor maximum diameter (to be irradiated) to be \</= 6 cm in the first 6 patients. If more than 1 target is irradiated, then the sum of all the target maximum diameters should be \</= 6 cm. No more than 3 separate targets for RT is allowed.
DRUGRetifanlimab
-Will be supplied by Incyte
Sponsors
Incyte Corporation
Washington University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Recurrent WHO grade 4 glioblastoma or gliosarcoma, including molecular features of glioblastoma and WHO grade 4 astrocytoma or WHO grade high grade glioma. * Other GBM variants and secondary GBM are allowed. All grade 4 gliomas that have relapsed more than once may be included, as the prognosis of multiply recurrent grade 4 glioma patients may not differ based on IDH mutation status. * Disease must have recurred, and patient must be a candidate for re-irradiation and bevacizumab. Any number of recurrences are allowed. * Patients must have measurable disease per RANO criteria. Lesions will be considered measurable when they are bi-dimensional with clearly defined margins of ≥5 mm in two perpendicular diameters. * Prior transient use of bevacizumab for cerebral edema or radiation necrosis is allowed without a washout period. Prior bevacizumab use is permitted if used for treatment of disease if administered more than 4 months prior to registration. * At least 18 years of age. * Karnofsky performance status ≥ 60% * Normal bone marrow and organ function as defined below: * Absolute neutrophil count ≥ 1,000/mcL * Platelets ≥ 75,000/mcL * Hemoglobin ≥ 9.0 g/dL or \> 5.6 mmol/L (transfusion is acceptable to meet this criterion) * Serum creatinine ≤ ULN or creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault for patients * Serum total bilirubin ≤ 1.5 ULN * AST(SGOT)/ALT(SGPT) ≤ 2.5 x IULN * INR or PT ≤ 1.5 x IULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants * aPTT ≤ 1.5 x IULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants * At least 28 days from any major surgery such as craniotomy and surgical wound is fully healed, and at least 14 days from LITT or biopsy. Prior to surgery, there must be imaging evidence of measurable progressive disease (PD) per RANO criteria as noted above. * Women of childbearing potential and men must agree to use highly effective contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. * Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). * Prior use of the Optune device is allowed, without a washout period. However, concurrent Optune use is not permitted while on treatment for this trial.
Exclusion criteria
* Currently receiving any other investigational agents. * A history of allergic reactions attributed to compounds of similar chemical or biologic composition to epacadostat, retifanlimab, bevacizumab, or other agents used in the study. * Dexamethasone dose \> 4 mg daily at the time of registration (higher dose of steroid for symptom control is allowed during the study). * History of intracranial abscess within 6 months prior to start of study therapy. * Has active autoimmune disease or syndrome (i.e. moderate or severe rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, active inflammatory bowel disease) that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) or who are receiving systemic therapy for an autoimmune or inflammatory disease (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Subjects are permitted to enroll if they have vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger. * Has a severe acute or chronic medical condition including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. * Has had an allogeneic tissue/solid organ transplant. * Has an active infection requiring intravenous antibiotic therapy. Has a known history of active tuberculosis (TB; bacillus tuberculosis). * Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or IDO inhibitor. * If a patient is enrolled to regimen B, they are prohibited from receiving monoamine oxidase inhibitors (MAOIs) or drug which has significant MAOI activity (meperidine, linezolid, methylene blue) within the 21 days before screening. * If a patient is enrolled to regimen B, the use of any UGT1A9 inhibitor from screening through follow-up period, including acitretin, amitriptyline, androsterone, cyclosporine, dasatinib, diclofenac, diflunisal, efavirenz, erlotinib, estradiol (17-beta), flutamide, gefitinib, gemfibrozil, glycyrrhetinic acid, glycyrrhizin, imatinib, imipramine, ketoconazole, linoleic acid supplements, mefenamic acid, mycophenolic acid, niflumic acid, nilotinib, phenobarbital, phenylbutazone, phenytoin, probenecid, propofol, quinidine, ritonavir, sorafenib, sulfinpyrazone, valproic acid, and verapamil is prohibited. * If a patient is enrolled to regimen B, the use of probiotics from screening through end of treatment is prohibited. * If a patient is enrolled to regimen B, the use of warfarin is prohibited. If anti-coagulation is needed during the conduct of the study and non-warfarin regimens are not feasible, the participant must discontinue study therapy. * Chronic use of systemic antibiotics (\> 14 days) unless medical monitor review and approval. * Any history of serotonin syndrome (SS) after receiving serotonergic drugs. * Has uncontrolled HIV (HIV 1/2 antibodies). Well-controlled HIV is defined as CD4+ count \> 300 cells, undetectable viral load, and receiving HAART/ART. Study specific HIV testing is not required for patients who do not have any prior history of HIV. * Has uncontrolled active hepatitis B (e.g., HBsAg reactive or HBV DNA detected by quant RT PCR) or hepatitis C (e.g. HCsAg reactive or HCV RNA \[qualitative or quantitative\] is detected). * Uncontrolled intercurrent illness including, but not limited to, clinically significant (i.e. active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 60 months prior to enrollment), congestive heart failure (≥ NYHA class II), unstable angina pectoris, or serious cardiac arrhythmia requiring medication. * History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful. Screening QTc interval \> 480 msec will require investigator's evaluation on patient's eligibility. Subjects with left bundle branch block are excluded. * Presence of a gastrointestinal condition that may affect drug absorption. * Receipt of live attenuated vaccine within 30 days before the first dose of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist) are live attenuated vaccines and are not allowed. * Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test prior to the start of study treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Kaplan-Meier Estimate of Overall Survival (OS) at 9 Months | At 9 months | Overall survival is defined as the time interval from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. If a patient has not had an event, OS will be censored at the date of last follow up. |
| Kaplan-Meier Estimate of Overall Survival (OS) at 12 Months | At 12 months | Overall survival is defined as the time interval from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. If a patient has not had an event, OS will be censored at the date of last follow up. |
| Median Overall Survival (OS) | Through 2 years after completion of treatment (estimated to be 4 years) | Overall survival is defined as the time interval from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. If a patient has not had an event, OS will be censored at the date of last follow up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 12 Months | At 12 months | * Duration of time from start of treatment to radiographic progression or death due to any cause, whichever occurs first * Radiographic progression will be assessed using the RECIST 1.1. If the disease recurrence/progression assessment involves more than one date, the earliest date will be used as the event date. A patient will be censored at the date of the last radiographic disease assessment indicating a lack of disease progression, if any of the following occurs before documented disease progression: alive and lack evidence of progression at the end of study or at the time of analysis data cut-off, disease progression or death occurs right after missing data for a scheduled radiographic disease assessment, patient receives non-protocol treatment, or equivocal findings of recurrence - treatment may continue until the next scheduled assessment. If recurrence is confirmed at the next scheduled assessment, the date of recurrence should be the earlier date when recurrence was suspected |
| Change in Neurologic Functions as Measured by the Neurologic Function in Neuro-Oncology (NANO) Scale | Screening (mean 9 days, range 1-21 days prior to treatment) & at last assessment (31/49 patients measured at end of treatment, 18 patients' last measurement was on Cycle 2-23 with a mean of 5.8 cycles) | * There are 9 domains (gait, strength, ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior). * Each domain is subdivided into 3 or 4 levels of function with scores based on discrete quantifiable measures. Each domain is scored from 0 to 3 points based on the severity of neurological deficit. A score of 0 indicates normal neurologic function, a score of 1 indicates mild impairment, 2 indicates severe impairment, and the highest score of 3 indicates the most severe level of deficit (incomplete hemianopsia) for that domain. Levels of function are distinguished by significant and measurable differences in order to avoid misinterpretation of subtle or nonspecific changes. * The total NANO score is the sum of the scores across all the 9 domains with a minimum score of 0 indicating normal function and a maximum score of 27 points indicating severe impairment. The total NANO score defines overall response criteria |
| Median Progression-Free Survival (PFS) | Through 2 years after completion of treatment (estimated to be 4 years) | * Duration of time from start of treatment to radiographic progression or death due to any cause, whichever occurs first * Radiographic progression will be assessed using the RECIST 1.1. If the disease recurrence/progression assessment involves more than one date, the earliest date will be used as the event date. A patient will be censored at the date of the last radiographic disease assessment indicating a lack of disease progression, if any of the following occurs before documented disease progression: alive and lack evidence of progression at the end of study or at the time of analysis data cut-off, disease progression or death occurs right after missing data for a scheduled radiographic disease assessment, patient receives non-protocol treatment, or equivocal findings of recurrence - treatment may continue until the next scheduled assessment. If recurrence is confirmed at the next scheduled assessment, the date of recurrence should be the earlier date when recurrence was suspected |
| Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | 90 days after completion of treatment (estimated to be 2 years and 90 days) | -The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting |
| Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 9 Months | At 9 months | * Duration of time from start of treatment to radiographic progression or death due to any cause, whichever occurs first * Radiographic progression will be assessed using the RECIST 1.1. If the disease recurrence/progression assessment involves more than one date, the earliest date will be used as the event date. A patient will be censored at the date of the last radiographic disease assessment indicating a lack of disease progression, if any of the following occurs before documented disease progression: alive and lack evidence of progression at the end of study or at the time of analysis data cut-off, disease progression or death occurs right after missing data for a scheduled radiographic disease assessment, patient receives non-protocol treatment, or equivocal findings of recurrence - treatment may continue until the next scheduled assessment. If recurrence is confirmed at the next scheduled assessment, the date of recurrence should be the earlier date when recurrence was suspected |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Regimen A: Retifanlimab+RT+Bevacizumab * Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.
* Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
* Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction
* Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy
* Treatment may continue for up to two years. | 24 |
| Regimen B: Retifanlimab+RT+Bevacizumab+Epacadostat * Retifanlimab will be given intravenously over the course of 30 to 60 minutes at a dose of 500 mg on Day 1 of each 28-day cycle.
* Bevacizumab will be given intravenously at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
* Ten fractions of radiation therapy will be given at a dose of 3.5 Gy per fraction
* Retifanlimab and bevacizumab will be started approximately two weeks before the first day of radiation therapy
* Epacadostat will be administered orally at 400 mg BID.
* Treatment may continue for up to two years. | 27 |
| Total | 51 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Did not start treatment | 0 | 2 |
Baseline characteristics
| Characteristic | Regimen A: Retifanlimab+RT+Bevacizumab | Total | Regimen B: Retifanlimab+RT+Bevacizumab+Epacadostat |
|---|---|---|---|
| Age, Continuous | 64 years | 62 years | 58 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 24 Participants | 50 Participants | 26 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 24 Participants | 50 Participants | 26 Participants |
| Region of Enrollment United States | 24 participants | 51 participants | 27 participants |
| Sex: Female, Male Female | 6 Participants | 14 Participants | 8 Participants |
| Sex: Female, Male Male | 18 Participants | 37 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 24 / 24 | 24 / 25 |
| other Total, other adverse events | 24 / 24 | 25 / 25 |
| serious Total, serious adverse events | 11 / 24 | 16 / 25 |
Outcome results
Primary
Kaplan-Meier Estimate of Overall Survival (OS) at 12 Months
Overall survival is defined as the time interval from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. If a patient has not had an event, OS will be censored at the date of last follow up.
Time frame: At 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Kaplan-Meier Estimate of Overall Survival (OS) at 12 Months | 50 percentage of participants-Kaplan Meier |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Kaplan-Meier Estimate of Overall Survival (OS) at 12 Months | 38 percentage of participants-Kaplan Meier |
Primary
Kaplan-Meier Estimate of Overall Survival (OS) at 9 Months
Overall survival is defined as the time interval from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. If a patient has not had an event, OS will be censored at the date of last follow up.
Time frame: At 9 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Kaplan-Meier Estimate of Overall Survival (OS) at 9 Months | 67 percentage of participants-Kaplan Meier |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Kaplan-Meier Estimate of Overall Survival (OS) at 9 Months | 67 percentage of participants-Kaplan Meier |
Primary
Median Overall Survival (OS)
Overall survival is defined as the time interval from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. If a patient has not had an event, OS will be censored at the date of last follow up.
Time frame: Through 2 years after completion of treatment (estimated to be 4 years)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Median Overall Survival (OS) | 11.53 months |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Median Overall Survival (OS) | 10.55 months |
Secondary
Change in Neurologic Functions as Measured by the Neurologic Function in Neuro-Oncology (NANO) Scale
* There are 9 domains (gait, strength, ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior). * Each domain is subdivided into 3 or 4 levels of function with scores based on discrete quantifiable measures. Each domain is scored from 0 to 3 points based on the severity of neurological deficit. A score of 0 indicates normal neurologic function, a score of 1 indicates mild impairment, 2 indicates severe impairment, and the highest score of 3 indicates the most severe level of deficit (incomplete hemianopsia) for that domain. Levels of function are distinguished by significant and measurable differences in order to avoid misinterpretation of subtle or nonspecific changes. * The total NANO score is the sum of the scores across all the 9 domains with a minimum score of 0 indicating normal function and a maximum score of 27 points indicating severe impairment. The total NANO score defines overall response criteria
Time frame: Screening (mean 9 days, range 1-21 days prior to treatment) & at last assessment (31/49 patients measured at end of treatment, 18 patients' last measurement was on Cycle 2-23 with a mean of 5.8 cycles)
Population: Last assessment indicates the last time that a patient had an assessment of neurologic function measured via the NANO scale. Regimen A N=14 and Regimen B N=17 had the last assessment at end of treatment. Regimen A N=10 and Regimen B N=8 had the last assessment during treatment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Change in Neurologic Functions as Measured by the Neurologic Function in Neuro-Oncology (NANO) Scale | Screening | 1.875 score on a scale | Standard Deviation 2.071 |
| Regimen A: Retifanlimab+RT+bevacizumab | Change in Neurologic Functions as Measured by the Neurologic Function in Neuro-Oncology (NANO) Scale | Last assessment | 2.952 score on a scale | Standard Deviation 2.906 |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Change in Neurologic Functions as Measured by the Neurologic Function in Neuro-Oncology (NANO) Scale | Screening | 2.12 score on a scale | Standard Deviation 2.333 |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Change in Neurologic Functions as Measured by the Neurologic Function in Neuro-Oncology (NANO) Scale | Last assessment | 3.273 score on a scale | Standard Deviation 2.865 |
Secondary
Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 12 Months
* Duration of time from start of treatment to radiographic progression or death due to any cause, whichever occurs first * Radiographic progression will be assessed using the RECIST 1.1. If the disease recurrence/progression assessment involves more than one date, the earliest date will be used as the event date. A patient will be censored at the date of the last radiographic disease assessment indicating a lack of disease progression, if any of the following occurs before documented disease progression: alive and lack evidence of progression at the end of study or at the time of analysis data cut-off, disease progression or death occurs right after missing data for a scheduled radiographic disease assessment, patient receives non-protocol treatment, or equivocal findings of recurrence - treatment may continue until the next scheduled assessment. If recurrence is confirmed at the next scheduled assessment, the date of recurrence should be the earlier date when recurrence was suspected
Time frame: At 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 12 Months | 25 percentage of participants-Kaplan Meier |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 12 Months | 4 percentage of participants-Kaplan Meier |
Secondary
Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 9 Months
* Duration of time from start of treatment to radiographic progression or death due to any cause, whichever occurs first * Radiographic progression will be assessed using the RECIST 1.1. If the disease recurrence/progression assessment involves more than one date, the earliest date will be used as the event date. A patient will be censored at the date of the last radiographic disease assessment indicating a lack of disease progression, if any of the following occurs before documented disease progression: alive and lack evidence of progression at the end of study or at the time of analysis data cut-off, disease progression or death occurs right after missing data for a scheduled radiographic disease assessment, patient receives non-protocol treatment, or equivocal findings of recurrence - treatment may continue until the next scheduled assessment. If recurrence is confirmed at the next scheduled assessment, the date of recurrence should be the earlier date when recurrence was suspected
Time frame: At 9 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 9 Months | 42 percentage of participants-Kaplan Meier |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Kaplan-Meier Estimate of Progression-Free Survival (PFS) at 9 Months | 21 percentage of participants-Kaplan Meier |
Secondary
Median Progression-Free Survival (PFS)
* Duration of time from start of treatment to radiographic progression or death due to any cause, whichever occurs first * Radiographic progression will be assessed using the RECIST 1.1. If the disease recurrence/progression assessment involves more than one date, the earliest date will be used as the event date. A patient will be censored at the date of the last radiographic disease assessment indicating a lack of disease progression, if any of the following occurs before documented disease progression: alive and lack evidence of progression at the end of study or at the time of analysis data cut-off, disease progression or death occurs right after missing data for a scheduled radiographic disease assessment, patient receives non-protocol treatment, or equivocal findings of recurrence - treatment may continue until the next scheduled assessment. If recurrence is confirmed at the next scheduled assessment, the date of recurrence should be the earlier date when recurrence was suspected
Time frame: Through 2 years after completion of treatment (estimated to be 4 years)
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Median Progression-Free Survival (PFS) | 6.98 months |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Median Progression-Free Survival (PFS) | 7.20 months |
Secondary
Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant
-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting
Time frame: 90 days after completion of treatment (estimated to be 2 years and 90 days)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Regimen A: Retifanlimab+RT+bevacizumab | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Vomiting | 1 Participants |
| Regimen A: Retifanlimab+RT+bevacizumab | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Aspartate aminotransferase increased | 0 Participants |
| Regimen A: Retifanlimab+RT+bevacizumab | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Diarrhea | 2 Participants |
| Regimen A: Retifanlimab+RT+bevacizumab | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Seizure | 4 Participants |
| Regimen A: Retifanlimab+RT+bevacizumab | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Alanine aminotransferase increased | 2 Participants |
| Regimen A: Retifanlimab+RT+bevacizumab | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Rash | 0 Participants |
| Regimen A: Retifanlimab+RT+bevacizumab | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Colitis | 1 Participants |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Rash | 3 Participants |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Colitis | 0 Participants |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Diarrhea | 0 Participants |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Vomiting | 1 Participants |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Alanine aminotransferase increased | 1 Participants |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Aspartate aminotransferase increased | 1 Participants |
| Regimen B: Retifanlimab+RT+bevacizumab+epacadostat | Safety and Toxicity of Regimen as Measured by Immune Related Grade 3 or Higher Adverse Events Experienced by Participant | Seizure | 5 Participants |